Skip to main content
EMVision Medical banner
EMVision Medical logo

EMVision Medical

EMVision Medical is developing a portable brain scanner for rapid, point of care, stroke diagnosis and monitoring.

Backed by

Keysight TechnologiesKeysight Technologies

Raised 10M EQUITY on February 28, 2024

About

EMVision develops emu, a portable non‑invasive neuroimaging device using ultra‑high‑frequency radio signals and AI for rapid bedside scans, plus a sub‑10kg first‑responder scanner; devices in clinical investigations.

Mission

EMVision develops the emu™, a portable, non‑invasive neuroimaging device that uses ultra‑high frequency radio signals and AI to produce rapid bedside brain scans. The company is scaling production and clinical trials to support regulatory approval and adoption in the US, with market entry for the emu™ planned for next year. EMVision is also developing a backpack‑sized first responder scanner (under 10 kg) intended for road and air ambulances to enable paramedics to scan suspected stroke patients on site. The company’s pipeline targets intensive care units, stroke and neurology wards, and rural emergency departments where CT/MRI access is limited. EMVision holds offices in Sydney and Brisbane and has an OEM supply partnership with Keysight that grants exclusivity for the VNA ""fast sweep"" feature. The emu™ and first responder devices are not yet FDA‑evaluated and are restricted to authorized sites in controlled clinical investigations. New capital from Keysight is intended to accelerate clinical trials, expand production capacity, and support commercialization efforts in the US.

Quick Facts

Founded

2017

Funding

EQUITY

Industry

Medical, Medical Device

Team Size

1-10

Headquarters

Brisbane, Queensland, Australia

EMVision Medical | Matchbox | Matchbox